Development of liposomal amphotericin B formulation

Area of Science:

• Pharmacology
• Drug Delivery Systems
• Mycology

Background:

• Conventional amphotericin B (AmB) has significant acute and chronic toxicities, including renal dysfunction and cardiotoxicity.
• Poor response rates to AmB were observed in immunocompromised patients, such as those with AIDS or undergoing chemotherapy.
• Liposomes emerged as a promising drug delivery system to improve drug efficacy and reduce side effects.

Purpose of the Study:

• To review the development and clinical utility of liposomal amphotericin B (L-AmB) as a novel drug delivery system.
• To evaluate the improved therapeutic index and reduced toxicity of L-AmB compared to conventional AmB.
• To assess the efficacy of L-AmB in treating deep-seated fungal infections in immunocompromised patients.

Main Methods:

• Review of in vitro, in vivo, and clinical studies on L-AmB.
• Analysis of biodistribution and pharmacokinetic data of L-AmB.
• Examination of formulation considerations and clinical experience with marketed L-AmB preparations.

Main Results:

• L-AmB demonstrated a significantly better therapeutic index and lower toxicity than conventional AmB, with a higher LD50 in mice (175 mg/kg for L-AmB vs. 3.7 mg/kg for conventional AmB).
• L-AmB exhibits prolonged circulation time and targeted delivery to infection sites, minimizing nephrotoxicity and neurotoxicity.
• Clinical studies confirmed the efficacy of L-AmB in treating fungal infections, particularly in immunocompromised individuals.

Conclusions:

• Liposomal encapsulation significantly enhances the safety and efficacy profile of amphotericin B.
• L-AmB represents a clinically valuable advancement in antifungal therapy, especially for vulnerable patient populations.
• Further research into liposomal drug delivery systems holds potential for improved therapeutic outcomes in various diseases.